跳至主要内容
临床试验/NCT07696572
NCT07696572招募中不适用

Registry of Patients Undergoing Endoscopic Ultrasound (EUS) Procedures Using the RIVOS™ EUS Access Device

Orlando Health, Inc.1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2026年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
30
试验地点
1
主要终点
Technical success

研究概览

简要总结

This is a prospective study of patients undergoing EUS procedures using the RIVOS™ EUS access device.

详细描述

Endoscopic ultrasound (EUS)-guided interventions are becoming the first-line treatment of various pancreaticobiliary disorders such as malignant biliary obstruction, access to bile duct or pancreatic duct after failed ERCP, and drainage of pancreatic, peripancreatic or intraabdominal fluid collections. However, given the lack of dedicated devices for performing these complex interventions, accessories used to perform endoscopic retrograde cholangiopancreatography (ERCP) are currently being used off-label to perform most interventional EUS procedures.

The RIVOS™ EUS access device is a novel, FDA approved device that has been specifically developed for performing EUS-guided interventions. The device has a sharp trocar tip to allow access to the target organ, a flexible access cannula to allow contrast injection and passage of a guidewire, and an electrocautery-tip to facilitate the creation of a fistula. This innovative design is expected to simplify the technical aspects of the procedure and improve the safety profile for these complex endoscopic interventions.

The aim of this study is to evaluate the technical and treatment outcomes in patients undergoing standard of care, interventional EUS-guided procedures in patients with pancreaticobiliary disorders using the RIVOS™ EUS access device.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • All patients undergoing EUS-guided interventions using the RIVOS™ EUS access device

排除标准

  • Age < 18 years
  • Patients who did not undergo EUS-guided interventions using the RIVOS™ EUS access device

结局指标

主要结局

Technical success

时间窗: 1 day

Rate of technical success in patients undergoing EUS-guided procedures

次要结局

  • Treatment success(4 weeks)
  • Adverse events(4 weeks)
  • Hospital admission(4 weeks)
  • Procedure duration(1 day)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验